Jacob P. Hoj

Jacob P. Hoj

Auto-generated profile, based on publicly available information

Jacob P. Hoj

Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
Peter FecciPeter Fecci
Peter Fecci
CCCosette D. Champion
Cosette D. Champion
JHJacob Hoj
Jacob Hoj
CMCourtney M. McKernan
Courtney M. McKernan
CGC. Rory Goodwin
C. Rory Goodwin
JSJohn H. Sampson
John H. Sampson
The incidence of brain metastases is increasing as cancer therapies improve and patients live longer, providing new challenges to the multidisciplinary teams that care for these patients. Brain metastatic cancer cells possess unique characteristics that allow them to penetrate the blood–brain barrier, colonize the brain parenchyma, and persist in the intracranial environment. In addition, brain metastases subvert the innate and adaptive immune system, permitting evasion of the antitumor immune response. Better understanding of the above mechanisms will allow for development and delivery of more effective therapies for brain metastases. In this review, we outline the molecular mechanisms underlying development, survival, and immunosuppression of brain metastases. We also discuss current and emerging treatment strategies, including surgery, radiation, disease-specific and mutation-targeted systemic therapy, and immunotherapy.

14 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SKShane T. Killarney
Shane T. Killarney
RWRachel Washart
Rachel Washart
RSRyan S. Soderquist
Ryan S. Soderquist
JHJacob P. Hoj
Jacob P. Hoj
JLJamie Lebhar
Jamie Lebhar
KWKris C. Wood
Kris C. Wood
During apoptosis, mitochondrial outer membrane permeabilization (MOMP) enables certain mitochondrial matrix macromolecules to escape into the cytosol. However, the fate of mitochondrial RNA (mtRNA) during apoptosis is unknown. Here, we demonstrate that MOMP results in the cytoplasmic release of mtRNA and that executioner caspases-3 and -7 (casp3/7) prevent cytoplasmic mtRNA from triggering inflammatory signaling. In the setting of genetic or pharmacological casp3/7 inhibition, apoptotic insults result in mtRNA activation of the MDA5/MAVS/IRF3 pathway to drive Type I interferon (IFN) signaling. This pathway is sufficient to activate tumor-intrinsic Type I IFN signaling in immunologically cold cancer models that lack an intact cGAS/STING signaling pathway, promote CD8+T-cell-dependent anti-tumor immunity, and overcome anti-PD1 refractoriness in vivo. Thus, a key function of casp3/7 is to inhibit inflammation caused by the cytoplasmic release of mtRNA, and pharmacological modulation of this pathway increases the immunogenicity of chemotherapy-induced apoptosis.

10 December 2019 in Cell Reports
Verified
Journal Article
Open access
JHJacob P. Hoj
Jacob P. Hoj
BMBenjamin Mayro
Benjamin Mayro
APAnn Marie Pendergast
Ann Marie Pendergast
Brain metastases are a common consequence of advanced lung cancer, resulting in cranial neuropathies and increased mortality. Currently, there are no effective therapies to treat brain metastases due to a lack of actionable targets and a failure of systemic therapies to penetrate the blood-brain barrier (BBB). Here we identify an autocrine signaling axis required for lung adenocarcinoma brain metastasis, whereby nuclear accumulation of the TAZ transcriptional co-activator drives expression of a panel of transcripts enriched in brain metastases, including ABL2 and AXL, encoding for protein tyrosine kinases that engage in bidirectional signaling. Activation of ABL2 in turn promotes TAZ tyrosine phosphorylation and nuclear localization, establishing an autocrine AXL-ABL2-TAZ feed-forward signaling loop required for brain metastasis colonization. Notably, treatment with a BBB-penetrant ABL allosteric inhibitor or knockdown of ABL2, AXL, or TAZ markedly decreases brain metastases. These findings suggest that ABL and AXL inhibitors might be effective against brain metastases.

6 June 2022 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
KLKevin H. Lin
Kevin H. Lin
JRJustine C. Rutter
Justine C. Rutter
AXAbigail Xie
Abigail Xie
SKShane T. Killarney
Shane T. Killarney
CVCamille Vaganay
Camille Vaganay
KWKris C. Wood
Kris C. Wood

14 December 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JHJacob P. Hoj
Jacob P. Hoj
BMBenjamin Mayro
Benjamin Mayro
APAnn Marie Pendergast
Ann Marie Pendergast
Significance: Among all cancer types, lung cancer patients exhibit the highest prevalence of brain metastasis, often associated with cognitive impairment, seizures, decline in quality of life, and decreased survival. Limited therapeutic options are currently available to treat brain metastasis. A comprehensive understanding of the signaling pathways and transcriptional networks required for survival and growth of brain-metastatic cancer cells is needed to develop effective strategies to treat this disease. Here, we report that the Heat Shock Transcription Factor 1 (HSF1) is upregulated in brain-metastatic lung cancer cells and is required for brain metastasis in mice. Importantly, we show that the HSF1-dependent expression of E2F target genes implicated in cell cycle progression and survival is decreased by blood–brain barrier-penetrant ABL allosteric inhibitors.

1 October 2021 in Cell Reports
Verified
Journal Article
Open access
JLJillian Hattaway Luttman
Jillian Hattaway Luttman
JHJacob P. Hoj
Jacob P. Hoj
KLKevin H. Lin
Kevin H. Lin
JLJiaxing Lin
Jiaxing Lin
JGJing Jin Gu
Jing Jin Gu
APAnn Marie Pendergast
Ann Marie Pendergast
Targeting mitochondrial metabolism has emerged as a treatment option for cancer patients. The ABL tyrosine kinases promote metastasis, and enhanced ABL signaling is associated with a poor prognosis in lung adenocarcinoma patients. Here we show that ABL kinase allosteric inhibitors impair mitochondrial integrity and decrease oxidative phosphorylation. To identify metabolic vulnerabilities that enhance this phenotype, we utilized a CRISPR/Cas9 loss-of-function screen and identified HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway and target of statin therapies, as a top-scoring sensitizer to ABL inhibition. Combination treatment with ABL allosteric inhibitors and statins decreases metastatic lung cancer cell survival in vitro in a synergistic manner. Notably, combination therapy in mouse models of lung cancer brain metastasis and therapy resistance impairs metastatic colonization with a concomitant increase in animal survival. Thus, metabolic combination therapy might be effective to decrease metastatic outgrowth, leading to increased survival for lung cancer patients with advanced disease.